OK SB1902

Prohibits provision of RU-486 (mifepristone) for abortion induction except by physicians meeting specific qualifications including ability to assess pregnancy duration, diagnose ectopic pregnancies, provide surgical intervention for complications, and ensure access to medical facilities with transfusion and resuscitation capabilities.

Requires physicians providing RU-486 to furnish patients with manufacturer's medication guide and patient agreement, fully explain the procedure including whether FDA-approved or evidence-based regimen is used, obtain signed patient agreement, and record drug package serial number in medical records.

Mandates RU-486 be administered by or in the physical presence of the prescribing physician and requires physicians make reasonable efforts to ensure patient follow-up 12-18 days after administration to confirm pregnancy termination and assess medical condition.

Requires physicians to report within 60 days to the drug manufacturer and their licensing board (State Board of Medical Licensure and Supervision or State Board of Osteopathic Examiners) any incomplete abortion, severe bleeding, adverse reactions, hospitalizations, transfusions, or serious events occurring within one year of RU-486 use.

Permits pregnant females, fathers (if married at time of abortion), or maternal grandparents to sue for actual and punitive damages against those knowingly or recklessly violating the law; provides for attorney fees; exempts the pregnant female herself from being subject to legal action.